<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="HE82AACE074AB4ABE9B5F8BD47E04B8B8" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>119 HR 946 IH: Optimizing Research Progress Hope And New Cures Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2025-02-04</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">119th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 946</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20250204">February 4, 2025</action-date><action-desc><sponsor name-id="J000302">Mr. Joyce of Pennsylvania</sponsor> (for himself, <cosponsor name-id="D000230">Mr. Davis of North Carolina</cosponsor>, <cosponsor name-id="H001082">Mr. Hern of Oklahoma</cosponsor>, <cosponsor name-id="P000608">Mr. Peters</cosponsor>, <cosponsor name-id="M001215">Mrs. Miller-Meeks</cosponsor>, <cosponsor name-id="K000375">Mr. Keating</cosponsor>, <cosponsor name-id="H001067">Mr. Hudson</cosponsor>, <cosponsor name-id="T000488">Mr. Thanedar</cosponsor>, <cosponsor name-id="B001257">Mr. Bilirakis</cosponsor>, and <cosponsor name-id="G000583">Mr. Gottheimer</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in addition to the Committee on <committee-name committee-id="HWM00">Ways and Means</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned</action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend title XI of the Social Security Act to expand and clarify the exclusion for orphan drugs under the Drug Price Negotiation Program.</official-title></form><legis-body id="HCED6BB2B16DC4E0A8BBB5930D259D8FE" style="OLC"><section id="H42FD894398504B4DACC48971161A7025" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Optimizing Research Progress Hope And New Cures Act</short-title></quote> or the <quote><short-title>ORPHAN Cures Act</short-title></quote>.</text></section><section id="HD65FA0EF330F4E77AAE1F3EF82B0E708"><enum>2.</enum><header>Expanding and clarifying the exclusion for orphan drugs under the Drug Price Negotiation Program</header><text display-inline="no-display-inline">Section 1192(e) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1320f-1">42 U.S.C. 1320f–1(e)</external-xref>) is amended—</text><paragraph id="H27838860B2294FA58B9B53FBB3100318"><enum>(1)</enum><text>in paragraph (1), by adding at the end the following new subparagraph:</text><quoted-block style="OLC" id="HE2CA17EC9C674F008B937FDBE9381870" display-inline="no-display-inline"><subparagraph id="H696F4417E1774E6791704EF43202F3EF"><enum>(C)</enum><header>Treatment of former orphan drugs</header><text display-inline="yes-display-inline">In calculating the amount of time that has elapsed with respect to the approval of a drug or licensure of a biological product under subparagraph (A)(ii) and subparagraph (B)(ii), respectively, the Secretary shall not take into account any period during which such drug or product was a drug described in paragraph (3)(A).</text></subparagraph><after-quoted-block>; and</after-quoted-block></quoted-block></paragraph><paragraph id="H5C3D461D2A5B4F379FA3A01D7CB30825"><enum>(2)</enum><text>in paragraph (3)(A)—</text><subparagraph id="H51C33560BB764528AE18F8420BA1AA0D"><enum>(A)</enum><text>by striking <quote>only one rare disease or condition</quote> and inserting <quote>one or more rare diseases or conditions</quote>; and </text></subparagraph><subparagraph id="H262457F3C8BF42DF90E2B7FFD8E0BE66"><enum>(B)</enum><text>by striking <quote>such disease or condition</quote> and inserting <quote>one or more rare diseases or conditions (as such term is defined in section 526(a)(2) of the Federal Food, Drug, and Cosmetic Act)</quote>. </text></subparagraph></paragraph></section></legis-body></bill> 

